

Table 2: Current clinical trials on redifferentiation therapy for thyroid cancer [98]

<b>Study</b>	<b>Condition</b>	<b>Treatment/intervention</b>	<b>Collaborators</b>	<b>Status</b>
<b>Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer</b>	recurrent thyroid cancer stage IV follicular thyroid cancer insular thyroid cancer stage IV papillary thyroid cancer	Drug: rosiglitazone Procedure: biological response modifier therapy, differentiation therapy, radiosensitization	University of California, San Francisco National Cancer Institute (NCI)	recruiting, pilot study
<b>FR901228 in Treating Patients With Refractory Thyroid Cancer or Other Advanced Cancer</b>	refractory thyroid cancer or other advanced cancer	Patients will receive a 4-hour infusion of FR901228 (depsipeptide) three times a week. Treatment may be repeated every 3 weeks for as long as benefit is shown.	NCI - Center for Cancer Research Warren Grant Magnuson Clinical Center	recruiting, phase I
<b>FR901228 in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine</b>	stage IV follicular thyroid cancer stage IV papillary thyroid cancer recurrent thyroid cancer	Drug: FR901228 (depsipeptide) Procedure: chemotherapy, enzyme inhibitor therapy	Memorial Sloan-Kettering Cancer Center National Cancer Institute (NCI)	recruiting, phase II
<b>Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131</b>	recurrent thyroid cancer stage IV follicular thyroid cancer stage IV papillary thyroid cancer	Drug: decitabine (5-aza-2'-deoxycytidine), iodine I 131 Procedure: chemotherapy, isotope therapy, radiation therapy	M.D. Anderson Cancer Center National Cancer Institute (NCI)	recruiting, phase II
<b>Multicentric Study for the Stimulation of Redifferentiation of Human Thyroid Cancer by Retinoic Acid ("MSSR Study")</b>	poorly differentiated follicular, papillary or oncocytic thyroid cancer, unresponsive to I-131	Drug: RA (first arm), RA + I-131 (second arm) Procedure: differentiation therapy, radiosensitization	Institute of Nuclear Medicine, University of Würzburg, other centers in (or outside of) Germany	recruiting, phase II/III
<b>Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer</b>	stage IV papillary thyroid cancer childhood head and neck cancer recurrent thyroid cancer stage IV follicular thyroid cancer	Drug: azacitidine, I-131, liothyronine	National Cancer Institute (NCI) University of Kentucky	completed phase I